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Abstract: Antiretroviral therapy (ART) has evolved considerably over the last three decades. 
From the early days of monotherapy with high toxicities and pill burdens, through to larger pill 
burdens and more potent combination therapies, and finally, from 2005 and beyond where we 
now have the choice of low pill burdens and once-daily therapies. More convenient and less 
toxic regimens are also becoming available, even in resource-poor settings. An understanding 
of the individual variation in response to ART, both efficacy and toxicity, has evolved over 
this time. The strong association of the major histocompatibility class I allele HLA-B*5701 
and abacavir hypersensitivity, and its translation and use in routine HIV clinical practice as a 
predictive marker with 100% negative predictive value, has been a success story and a notable 
example of the challenges and triumphs in bringing pharmacogenetics to the clinic. In real 
clinical practice, however, it is going to be the exception rather than the rule that individual 
biomarkers will definitively guide patient therapy. The need for individualized approaches to 
ART has been further increased by the importance of non-AIDS comorbidities in HIV clinical 
practice. In the future, the ideal utilization of the individualized approach to ART will likely 
consist of a combined approach using a combination of knowledge of drug, virus, and host 
(pharmacogenetic and pharmacoecologic [factors in the individual’s environment that may be 
dynamic over time]) information to guide the truly personalized prescription. This review will 
focus on our knowledge of the pharmacogenetics of the efficacy and toxicity of currently available 
antiretroviral agents and the current and potential utility of such information and approaches in 
present and future HIV clinical care.
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Introduction and current antiretroviral use
Since the recognition of AIDS as a clinical syndrome 30 years ago there have been 
26 drugs approved for the HIV treatment (Figure 1). Early treatment of HIV was bur-
dened with the inconvenience and intolerance of high-dose drugs such as zidovudine 
in the absence of improved monitoring with viral load and resistance testing. This 
type of treatment evolved into sequential monotherapy and finally in the mid-1990s 
into the true era of highly active antiretroviral therapy (HAART), when combination 
antiretroviral therapy (ART) with three or more agents became the norm. These early 
HAART years were marked by regimens that had high pill burdens and toxicities and, 
although efficacious, were hard to adhere to and tolerate. Early fixed-dose combina-
tion with newer nucleoside reverse transcriptase inhibitors (NRTIs) led to smaller pill 
burdens, and these later-generation NRTIs also had fewer toxicities. This evolved to 
the development of once-daily drugs with fewer pill burdens and toxicities across Pharmacogenomics and Personalized Medicine 2012:5 submit your manuscript | www.dovepress.com
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1987 –Zidovudine (AZT)
1991 –Didanosine (ddl)
1992 –Zalcitabine
1994 –Stavudine
1995 –Iamivudine, hard gel saquinavir
2001 –tenofovir
2003 –T-20, atazanavir, emtricitabine, fosamprenavir
1996 –nevirapine ritonavir, indinavir
1997 –delavirdine, nelfinavir, soft gel saquinavir
1998 –abacavir efavirenz
1999 –amprenavir
2000 –Iopinavir/ritonavir
2005 –tipranavir
2006 –darunavir
2007 –maraviroc
2008 –raltegravir
–Integrase inhibitors
–Entry inhibitors
–Nonnucleoside reverse
transcriptase inhibitors
–Protease inhibitors
–Nucleoside/tide reverse
transcriptase inhibitors
2011 –rilpivirine
–etravirine
1987 – first NRTI approved
1995 – first PI approved
1996 – first NNRTI approved
2003 – first entry inhibitor
approved
2008 – first integrase
inhibitor approved
Timeline of antiretrovirals
Figure 1 Timeline of antiretrovirals.
Abbreviations: NNRTi, non-nucleoside reverse transcriptase inhibitor; NRTi, nucleoside reverse transcriptase inhibitor; Pi, protease inhibitor.
the NRTI, non-nucleoside reverse transcriptase inhibitor 
(NNRTI), and protease inhibitor classes (Figure 1).
HIV is a chronic proinflammatory illness and, if left 
untreated, results in chronic CD4+ T-cell count depletion. 
The decision on when to start antiretroviral drugs has 
traditionally been based on the degree of immunosuppres-
sion, and evidence-based medicine unequivocally supports 
the initiation of therapy with CD4 T-cell counts of 350/µL 
or lower.1–4 An increasing body of observational literature 
supports much earlier initiation of ART, and this has been 
supported by increasing knowledge of the basic science of 
inflammation in relation to chronic HIV infection (Table 1).1–4 
The evolution of less toxic and more convenient antiretro-
viral agents (Figure 1) and the current landscape of HIV 
treatment guidelines (Tables 1 and 2) have driven and dem-
onstrate the significant shift toward earlier treatment of HIV , 
  respectively. Introduction of newer, more convenient, and 
highly tolerable drugs near the end of this past decade has led 
to more treatment options for HIV . In the developed world, 
in particular, we currently have the luxury of individualizing 
ART based on specific characteristics of the drug, virus, and 
host (Figure 2). Characteristics of the drug that may play into 
the decision of treating a specific individual will include its 
toxicity profile, convenience, pill burden, and penetration into 
the central nervous system (CNS) and other sanctuary sites. 
Characteristics of the virus influencing drug choice include 
the viral resistance pattern demonstrated on genotypic and/or 
phenotypic testing and the history of previous antiretroviral 
use in treatment-experienced patients. More recently, C-C 
chemokine receptor type 5 (CCR5) antagonists such as mara-
viroc have been developed, which inhibit a host chemokine 
receptor utilized by a proportion of HIV , particularly early 
in the disease. Genotypic and phenotypic tropism assays 
are utilized to ascertain whether HIV and the population of 
viruses in a specific patient are likely to be CCR5 tropic and 
respond to treatment with these agents.5,6
Finally, characteristics of the host are very   important 
in the individualization of ART and comprise both 
  pharmacoecologic (factors in the individual’s environment 
that may be dynamic over time) and pharmacogenetic   factors.7 
Pharmacoecologic factors that influence our   day-to-day pre-
scribing in the individual include factors relating to   lifestyle Pharmacogenomics and Personalized Medicine 2012:5 submit your manuscript | www.dovepress.com
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and adherence of the patient, drug interactions, underlying 
organ dysfunction such as hepatitis or renal disease, or 
pregnancy. Chronic hepatitis B infection is an important 
consideration because specific antiretroviral drugs such as 
lamivudine (2′,3′-dideoxy-3′-thiacytidine), emtricitabine 
(FTC), and tenofovir have activity against hepatitis B.
Non-AIDS comorbidities such as vascular disease, end-
organ dysfunction, and cancer are playing an increasing role 
in the decision to individualize therapy. Antiretroviral drugs 
with benign metabolic profiles, for instance, are likely to be 
easier to use in an aging population either with or at risk for 
vascular disease. A more fixed aspect of the host that relates 
to individualization of ART is pharmacogenetic factors that 
potentially affect drug efficacy and toxicity. These include 
genes that may affect the overall disposition and activity 
of a drug, such as those related to absorption, distribution, 
metabolism, and excretion; drug transport; or the drug target 
itself. These may also include immune response or human 
leukocyte antigen (HLA) genes that appear to be particu-
larly important in specific types of immunologically medi-
ated drug toxicities. The discovery of a strong association 
between the major histocompatiblity complex (MHC) class I 
allele HLA-B*5701 and abacavir hypersensitivity and the 
subsequent widespread utilization of this marker in routine 
HIV clinical practice is a major example of the translation 
of   pharmacogenetics in the individualization of ART.8–10 
Many other examples exist that have not currently been or 
will not be amenable to clinical translation. The remainder 
of this review article will focus on pharmacogenetic aspects 
of variation in antiretroviral drug response and the prospects 
for utilization of this knowledge in individualizing ART.
Pharmacogenetics  
of antiretroviral drugs
Pharmacokinetic and efficacy correlations
Amongst antiretroviral drugs, the NNRTIs and protease 
inhibitors, in particular, are associated with significant 
interindividual variation in drug exposure, which is 
largely driven by genetic differences in drug transporters, 
nuclear receptors, and drug-metabolizing enzymes. 
Although the pharmacogenetics of these drugs is becoming 
well established and pharmacokinetic/pharmacogenetic 
relationships are established for some drugs, reports directly 
correlating genetic differences in absorption, distribution, 
Table 1 Comparison of recommendations on when to start, based on CD4+ cell count
CD4 ,200/μL CD4 200–350/μL CD4 350–500/μL CD4 .500/μL
Department of Health and Human Services 20111     (optional)
international AiDS Society 20102    Consider
european AiDS Clinical Society 20093   Select only Deferral
world Health Organization 20104   X X
Abbreviation: AIDS, acquired immune deficiency syndrome.
Table 2 what to start for Hiv treatment naive patients – DHHS guidelines 2011
Preferred regimens EFV or 
ATV)/r or 
DRV/r or         
+ TDF/FTC 
RAL 
Pregnant Women: LPV/r (twice daily)+ + ZDV/3TC
Alternative regimens* eFv + ABC or ZDv/3TC
NvP + ZDv/3TC
ATv/r + (ABC or ZDv)/3TC
FPv/r (once or twice daily) + either (ABC or ZDv)/3TC or TDF/FTC
Acceptable regimens eFv + ddi + (3TC or FTC)
ATv + (ABC or ZDv)/3TC
MvC + ZDv/3TC
Data lacking MvC + either ABC/3TC or TDF/FTC
RAL + (ABC/ZDv) /3TC
DRv/r or SQv/r + (ABC or ZDv)/3TC
*as of August 2011, rilpivirine, a second generation non-nucleoside reverse transcriptase inhibitor has now been approved for second-line use in combination ART in 
treatment naive patient1
+Once daily LPv/r (800/200 mg) is not recommended in pregnancy. Based on published pharmacokinetic studies it is generally recommended that the dose of LPv/r be 
increased to 600 mg/150 mg p.o. bid for the second and third trimesters.
Abbreviations: eFv, efavirenz; ATv, atazanavir; r, ritonavir; DRv, darunavir; TDF, tenofovir; FTC, emtricitibine; RAL, raltegravir; LPv, lopinavir; ZDv, zidovudine; 3TC, 
laminudine; ABC, abacavir; NvP, nevirapine; FPv, fosamprenavir; TDF, tenofovir; ddi, didanosine; MvC, maraviroc; RAL, raltegravir; SQv, saquinavir; DHHS, Department of 
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metabolism, and excretion and drug transporter genes with 
treatment efficacy and response have been inconsistent. 
There are currently no large published studies that have 
directly examined the use of pharmacogenetics to guide 
antiretroviral dose. As such, although some have advocated 
using approaches   combining therapeutic drug monitoring 
with   pharmacogenetics, pharmacogenetics of the individual 
patient is generally not widely used in clinical practice in an 
attempt to improve treatment efficacy.11
Non-nucleoside reverse transcriptase 
inhibitors
Nevirapine and efavirenz are still two of the most common 
NNRTIs in clinical use. For efavirenz, toxicity and efficacy 
pharmacokinetic relationships have been established.12 There 
is wide interindividual variability in nevirapine and efavirenz 
plasma exposure, explained to a great extent for efavirenz 
by cytochrome P450 2B6 (CYP2B6), the main isoenzyme 
involved in the major metabolic pathway 8-hydroxylation 
(and to a lesser extent in 7-hydroxylation). For the gene 
CYP2B6, more than 30 alleles have been identified, and sev-
eral of these result in a complete or partial loss of function. 
Depending on the alleles present, the CYP2B6 genotype may 
be described as extensive, intermediate, or slow metabolizing, 
and in the situation where CYP2B6 is impaired, alternative 
metabolic genes may then have increased importance.13–17 
In addition to CYP2B6, which is responsible for 77%–92% 
of efavirenz clearance, efavirenz is metabolized to a lesser 
degree by CYP3A4/5, CYP2A6, and UDP-glucuronosyl-
transferase-2B7 (UGT2B7) enzymes.18 Efavirenz is also 
known to induce CYP2B6, CYP3A4, P-  glycoprotein, and 
some UGT1 enzymes.
The most extensively studied single nucleotide polymor-
phism (SNP) in relation to both nevirapine and efavirenz 
metabolism is CYP2B6 516G.T, which marks the slow 
metabolizing haplotypes containing alleles CYP2B6*6,*7, 
*9, and *13. These alleles result in a pronounced decrease in 
CYP2B6 expression and activity, as well as a low rate of efa-
virenz 8-hydroxylation.19,20 The 516 T allele is found at a sig-
nificantly higher frequency in Sub-Saharan Africans (45.5%) 
and African Americans (46.7%) as compared with Hispanic 
(27.3%), European (21.4%), and Asian (17.4%) popula-
tions.21–23 CYP2B6 516G.T homozygosity is significantly 
associated with greater plasma and intracellular exposure to 
efavirenz and greater plasma exposure to nevirapine across 
a variety of ethnicities and in both adults and children.24–37 
Characteristics of
drug or drug
combination
Virus Host
• Toxicity profile
• Phenotypic/genotypic
   resistance pattern
   and/or history of
   antiretroviral use
• Immunogenetic/HL
   A (eg, HLA-B*5701
   for abacavir
   hypersensitivity)
Pharmacogenetic Pharmacoecologic
• ADME genes
• Drug transporter
  genes
• Adherence
• LIfestyle
• Drug interactions/
   concurrent
   medications
• Non-AIDS co-
   morbidities
• Organ dysfunction
• Chronic hepatitis B
• Pregnancy
• Drug target genes
Revision of
dose/drug regimen
as necessary
• CCR5 tropism
• Clade
Declaration of patient “phenotype” through
follow-up (Clinical and laboratory monitoring
for toxicity and efficacy – CD4 cell count, viral
load, therapeutic drug monitoring etc)
• Potency
• Convenience
• Fixed dose
• Pill burden
• CNS/sanctuary
site penetration
Individualized antiretroviral prescription
Figure 2 individualized antiretroviral prescription.
Abbreviation: CNS, central nervous system; CCR5, C-C Chemokine receptor type 5; AIDS, acquired immune deficiency syndrome; HLA, human leukocyte antigen; ADME, 
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Although many have associated CYP2B6 polymorphisms 
with nevirapine metabolism, concluding similar effects 
for both efavirenz and nevirapine metabolism,30,34 several 
conflicting studies are reported.38,39 In general, it appears that 
the effect of slow metabolizer CYP2B6 alleles on nevirapine 
area under the plasma drug concentration versus time curve 
(AUC) is less extreme.
A less frequent CYP2B6 polymorphism, 983T.C, also 
predicts plasma efavirenz pharmacokinetics and, in fact, 
improves the predictive ability of CYP2B 516G.T.25,27,40  This 
SNP characterizes haplotypes containing the slow metaboliz-
ing alleles CYP2B6*16 and *18. Further, slow metabolizer 
alleles for CYP2B6 are genetically linked to the SNPs 
136A.6 (CYP2B*11A, *11B), 1172T.A (CYP2B*15A, 
*15B), 499C.G, 516G.T, 785A.G (CYPB*26), 593T.C 
(CYP2B*27), and 1132C.T (CYP2B*28).24,41,42 Further-
more, a hybrid allele, CYP2B6*29, carries two amino acid 
substitutions, Q172H and M198T, associated with impaired 
enzyme function, and carriers show increased AUC when 
compared with extensive metabolizer genotypes.42,43 Carri-
ers of the allele CYPA6*17 (marked by 76A.T, 83A.G, 
85C.A, 86G.C, 933C.T) show a 1.8 times higher median 
efavirenz concentration (P = 0.017) compared with non-
carriers.15 In a study that fully resequenced CYP2B6 and 
genotyped 15 relevant SNPs in 169 participants, 45% car-
ried a loss/diminished function allele. Median AUC levels 
were more than doubled in individuals homozygous for a 
loss/diminished function allele compared with carriers and 
noncarriers.42 Another study that characterized CYP2B6 
haplotypes with three SNPs (rs10403955, rs2279345, and 
rs8192719) found an association between carriers of four to 
six of these three alleles and the risk of high (.4000 µg/L) 
efavirenz plasma concentrations.44
In general, it appears that slow metabolizer genotypes 
benefit from decreased drug doses. However, there is some 
evidence that such genotypes may confer some virologic 
benefit. In the case of efavirenz, it may be that the drug itself 
was approved at a higher than needed dose for most of the 
population. The ENCORE (Evaluation of Novel Concepts in 
Optimization of Antiretroviral Efficacy) study is a random-
ized clinical trial that is currently examining the efficacy of 
the standard 600 mg daily of efavirenz versus 400 mg daily, 
and has a genetic substudy. Reduced clearance of nevirapine 
with the CYP2B6-516-T/T genotype was accompanied by 
a beneficial increase in CD4+ T cell from baseline to week 
24 in one study.31 More recently, slow efavirenz metabolizers 
with the 516/983 genotypes displayed decreased virologic 
failure in African ethnicities.25 One explanation may be 
that sustained high efavirenz concentrations during brief 
periods of nonadherence may allow continued control of 
HIV-1 replication. This later finding was not seen across all 
ethnicities and thus requires replication in other cohorts. In 
all, drug metabolism should be considered together with 
CD4+ count when considering dose adjustments.
When CYP2B6 function is impaired, the relevance 
of accessory metabolic pathways utilizing CYP2A6 and 
CYP3A4/5 in limiting drug accumulation may increase.13,14 
Without consideration for CYP2B6 function, the data 
regarding CYP2A6 and CYP3A4/5 are conflicting. When 
considered in isolation, a weak association between the 
promoter SNP CYP3A4*B (–392A.G) and CYP3A5*3 
(6986A.G) and plasma efavirenz exposure was suggested 
in an analysis of 154 participants.33 However, subsequent 
studies that have examined these SNPs and, in addition, 
CYP3A4*2 have found that although these splice defects 
reduce enzyme activity, there is no influence on the metabo-
lism of efavirenz or nevirapine.28,30,39,45–47 Subsequent 
studies that have considered the dual effect of CYP2B6 
have shown that the CYP2A6 slow metabolizer variant 
carriers (*9 or *17) and CYP3A4/A5 accessory pathways 
appear to influence efavirenz elimination independent of 
CYP2B6.13–15 The cumulative influence of CYP2B6, CYP2A6, 
and CYP3A4_rs4646437 allelic variants on clearance implies 
a critical 90% decrease of efavirenz elimination in triple-
Hom-loss of function (LOF) individuals.13 A similar study 
examining efavirenz concentrations in 169 patients in the 
Swiss HIV cohort found that the effect of the CYP2A6*7, 
*9, and/or *17 alleles was observed only in patients with 
CYP2B6 slow metabolizer genotypes.14 In this group, carri-
ers of one or two CYP2A6 diminished (DOF)/LOF alleles, 
when compared with CYP2A6 extensive metabolizers, 
showed decreased metabolites of 8-hydroxylation efavirenz 
and 7-hydroxylation together with increased metabolites of 
N-glucuronidation of efavirenz.14 These results are consis-
tent with the role of CYP2A6 as an alternative pathway in 
efavirenz metabolism, and the role of N-glucuronidation 
in the setting of multiple DOF/LOF alleles in the main and 
accessory hydroxylating pathways.14
The UDP-glucuronsyltransferases (UGT1A1 and 
UGT2B7) are a diverse group of enzymes that transform 
small lipophilic molecules into water-soluble, excretable 
metabolites. UDP-glucuronosyltransferase (UGT) 2B7 is the 
main UGT isoform responsible for the efavirenz glucuronida-
tion, which may increase in importance in the background Pharmacogenomics and Personalized Medicine 2012:5 submit your manuscript | www.dovepress.com
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of impaired CYP function as mentioned.14,18 Another study 
that examined efavirenz plasma concentration in relation 
to UGT1B27, CYP2B6, and CYP2A6 genotypes found 
UGT2B7*1a carrier status to be an independent predictor for 
efavirenz concentration and accounted for 10.1% of the total 
variance in the drug metabolism in Ghanaian patients.16
In an in vitro heterologous system, conjugation of efa-
virenz by UGTB27 was examined together with atazanavir 
metabolism, another drug also known to be glucuronidated 
by UGTB27. Each of the drugs was found to be inhibited 
by the other, and this raises another level of complexity in 
the genotype/phenotype relationship of drug metabolism.18 
Similarly, the presence of concurrent therapies may also 
affect the function of key CYP enzymes in the metabo-
lism of efavirenz. Tenofovir, a nucleotide analog reverse 
transcriptase inhibitor, exacerbates the effect on efavirenz 
AUC in LOF/DOF homozygotes.42 Rifampicin is a known 
inducer of the P450 enzymes CYP2B6, CYP3A, CYP2C19, 
CYP2C8, CYP2C9, and CYP1A2, and despite its well-known 
interaction potential it is commonly used in the treatment 
of HIV/AIDS patients coinfected with tuberculosis.48 As a 
CYP2B6 enzyme inducer, rifampin coadministration would 
be expected to enhance efavirenz clearance and reduce 
plasma levels. However, a recent study found that patients 
with CYP2B6 516T/T slow metabolizing genotype receiving 
concomitant antituberculous therapy have higher efavirenz 
plasma concentrations than those volunteers with the same 
genotype but not receiving antituberculous therapy.49 This 
paradoxical effect of antituberculous therapy may be due to 
increased susceptibility of the CYP2B6 516G.T variant to 
inhibition by one (or more) of the antituberculous drugs as 
compared with the reference CYP2B6 enzyme. Alternatively, 
efavirenz metabolism may be inhibited by effects on the non-
CYP2B6 accessory pathways, leading to higher efavirenz 
concentrations.49 Further studies are needed to determine 
the mechanism.
The multidrug resistance 1 (MDR1) gene encodes an 
adenosine triphosphate (ATP)-binding cassette (ABC) trans-
porter, P-glycoprotein, which is present in the intestine, liver, 
kidney, and blood-brain barrier and on T lymphocytes. The 
role of this transporter in the response to efavirenz-containing 
regimens is controversial, as efavirenz does not appear to be 
a substrate for P-glycoprotein.50 Two studies have suggested 
that MDR1 3435C.T predicts more favorable virologic 
responses to efavirenz and nelfinavir treatment with the 
MDR1 T/T genotype, correlating with a greater rise in CD4 
cell count after 6 months and the best recovery of naive 
CD4 cells.45,47 Contrasting studies looking at CD4 count have 
reported a marginal association with MDR1 1236 but not 
at MDR1 2677 or MDR1 3435, or, in fact, a lower increase 
in CD4 cell count after efavirenz therapy initiation.26,51,52 
  However, others have found no correlation between MDR1 
SNPs and virologic success or immunologic failure.52,53 
Similarly, there are conflicting findings with the SNP MDR1 
2677G.T, which is in linkage disequilibrium with MDR1 
3434C.T and was originally reported to be associated with 
decreased efavirenz resistance.33 A supporting study found 
virologic failure was associated with a two-locus interaction 
between MDR1 2677G.T and CYP2B6 516G.T, which 
also correlated with higher efavirenz AUC24 values. More 
recently, a novel variant allele in MDR1 4036A.G was a 
major predictor of efavirenz plasma exposure in a healthy 
Ugandan population after single-dose administration. 
  Efavirenz relative bioavailability was 26% higher in subjects 
homozygous for the SNP.41 Although both MDR1 (2677 
G.T/A, 3435 C.T) genotypes have not been associated 
with any effect on nevirapine pharmacokinetics or plasma 
concentrations,28,30,39 nevirapine cerebrospinal fluid:plasma 
ratios are higher in children with the MDR1-3435-C/T or 
-T/T genotypes in comparison with those with the MDR1-
3435-C/C genotype.31
Etravirine is a newer second-generation NNRTI that 
shows efficacy in patients with primary NNRTI   mutations.54 
It is primarily hepatically metabolized by CYP3A4, 
CYP2C9, and CYP2C19. It is also an inhibitor of CYP2C9 
and CYP2C19 and an inducer of CYP3A4.54 Carriers of 
CYP2C9*3 and CYP2C19*2 have lower etravirine clearance. 
However, there has been no established impact on clinical 
outcome.55
Protease inhibitors
Although several studies have associated drug concentration/
pharmacogenetic relationships for various HIV protease 
inhibitors, these have been inconsistent, many have not been 
replicated, and pharmacogenetic efficacy relationships have 
yet to be established. The most commonly used protease 
inhibitors in HIV clinical practice that are combined with 
ritonavir as a boosting agent are atazanavir, darunavir, 
and lopinavir. CYP3A4 is predominantly involved in the 
metabolism of all HIV protease inhibitors. Protease inhibitors 
are also CYP3A inhibitors, with ritonavir being the most 
potent, and hence it is routinely used as a booster to increase 
plasma exposure of other protease inhibitors that are paired 
with it. Protease inhibitors are also substrates for the drug 
transporter P-glycoprotein. The pregnane X receptor (PXR) 
may explain the dual influence of CYP3A4 and MDR1 on Pharmacogenomics and Personalized Medicine 2012:5 submit your manuscript | www.dovepress.com
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the protease inhibitors such as atazanavir. PXR expression 
is correlated with CYP3A4 in liver in the absence of enzyme 
inducers. The PXR SNP 63396C→T alters PXR expression 
and CYP3A4 activity in vitro. Homozygosity for the T allele 
for PXR 63396 is associated with higher atazanavir clearance, 
likely mediated through an effect on hepatic PXR expression 
and   therefore expression of its target genes (eg, CYP3A4, 
solute carrier organic anion transporter family member 1B1 
(SLCO1B1), and MDR1), which are known to be involved 
in atazanavir clearance.56,57 A recent study examining PXR, 
CYP3A4, and CYP2B6 polymorphisms in a cohort of 1013 
Africans found that darunavir, fosamprenavir, lopinavir, 
nelfinavir, and tipranavir increased CYP3A4 and/or CYP2B6 
promoter activity, some through constitutive receptor 
but mainly through PXR. Addition of low-dose ritonavir 
enhanced levels of CYP promoter activity for several 
protease inhibitors. Some PXR variants displayed lower 
fosamprenavir- and lopinavir-induced CYP3A4 promoter 
activity than the PXR reference sequence, whereas efavirenz 
and nelfinavir induction was unchanged. The presence of 
PXR polymorphisms can therefore alter the induction of 
CYP3A4 and CYP2B6 promoter activity, potentially adding to 
the unpredictable nature of antiretroviral drug interactions.58 
Studies have suggested a correlation between efficacy and 
toxicity and lopinavir/ritonavir exposure. More recent studies 
have associated a polymorphism in the organic anion-
transporting polypeptide 1B1 (OATP1B1) hepatic influx 
drug transporter gene SCLO1B1 521 T.C with increased 
exposure to lopinavir and a polymorphism in intron 2 
(rs4149032) of SLCO1B1 with a lower lopinavir Cmin.59,60 
Another pharmacokinetic/pharmacogenetic modelling study 
suggested that 5% of lopinavir variability could be explained 
by genetic factors.61
integrase and CCR5 inhibitors
Raltegravir is the only HIV integrase inhibitor currently 
approved for clinical use in the treatment of naive and 
experienced patients. Raltegravir is metabolized by UGT1A1. 
Although early studies that looked at an association 
between the UGT1A1*28/*28 genotype and raltegravir 
plasma concentrations showed higher concentrations in 
those with the UGT1A1*28/*28 genotype, these were 
not thought to be   clinically significant.62 Maraviroc is a 
CCR5 receptor antagonist that works in patients who have 
a CCR5 trophic HIV virus. Maraviroc is also a substrate 
for CYP3A4. Previous studies have shown no difference 
in virologic response to maraviroc-based antiretroviral 
according to CCR5 ∆32 genotype in 982 patients genotyped 
in the MOTIVATE (Maraviroc versus Optimized Therapy 
in Viremic Antiretroviral Treatment-experienced Patients) 
1 and 2 studies.63
Pharmacogenetics of antiretroviral  
drug toxicity
Drug toxicities mediated through  
a primary immunologic mechanism
Adverse drug reactions can be clinically classified into type 
A reactions that are predictable based on the pharmacologic 
action of the drug and tend to be dose-dependent, and type B 
reactions that are less dependent on dose, are not predictable 
based on the pharmacology of the drug, and are thought to 
be largely genetically mediated. Although type B reactions 
comprise only 20% or less of all adverse drug reactions, 
they are often associated with a very high morbidity and 
mortality. Many type B reactions are also immunologically 
mediated. Immunologically mediated drug reactions have 
traditionally been categorized according to the classification 
of Gell and Coombs type I–IV. Most antiretroviral drugs 
have been associated with Gel-Coombs type IV   reactions or 
delayed hypersensitivity. Delayed hypersensitivity   reactions 
more commonly consist of a mild to moderate skin rash 
occurring .72 hours after drug initiation. More severe 
reactions include drug hypersensitivity reactions consist-
ing of fever, rash, and internal organ involvement; internal 
organ involvement alone; and severe skin syndromes such 
as Stevens-Johnson syndrome/toxic epidermal necrolysis 
(SJS/TEN). Antiretroviral drugs most commonly associ-
ated with delayed skin rashes, delayed drug hypersensitivity 
syndromes, drug-induced hypersensitivity syndrome/drug 
reaction with eosinophilia and systemic symptoms, and 
hepatitis include abacavir, NNRTIs (nevirapine, efavirenz), 
and fosamprenavir. More recently, associations between 
the MHC and drug hypersensitivity syndromes have been 
described for abacavir and nevirapine.
Abacavir
Abacavir is a guanosine nucleoside analog acting as an 
HIV reverse transcriptase inhibitor that has been approved 
for clinical use since 1998 in combination with other 
antiretroviral drugs. The major treatment-limiting toxicity of 
abacavir is a drug hypersensitivity syndrome, which consists 
of fever, malaise, gastrointestinal symptoms, and later, skin 
rash,   typically occurring in the second week after treatment 
initiation in approximately 5% of those initiating the drug. 
Most of the morbidity and mortality of abacavir hypersen-
sitivity occurs on rechallenge, which is contraindicated in Pharmacogenomics and Personalized Medicine 2012:5 submit your manuscript | www.dovepress.com
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those who have previously experienced such symptoms in 
association with abacavir.
First clues to a potential genetic association with abacavir 
hypersensitivity came with postmarketing experience show-
ing a lower frequency of abacavir hypersensitivity in black 
and Asian populations.64 A case report also documented 
abacavir hypersensitivity in a father and daughter. In 2002, 
two groups independently described a strong association 
between the HLA class I allele, HLA-B*5701, and abacavir 
hypersensitivity syndrome.65 The major barrier to the early 
application of HLA-B*5701 as a screening test to predict 
and prevent abacavir hypersensitivity was the apparent less 
than 100% negative predicative value in these early studies 
and subsequent case-control studies that included non-white 
populations.66 It was later discovered that this imperfect and 
apparent less than 100% negative predictive value was not real 
but was driven by the high false-positive clinical diagnosis of 
abacavir hypersensitivity in these early studies. Highlighting 
this, randomized double-blind clinical trials that included 
abacavir also consistently showed that between 2% and 7% 
of patients in the nonabacavir arms were given a diagnosis 
of abacavir hypersensitivity.67–70   Abacavir skin patch testing 
was later successfully used to define the true phenotype of 
immunologically mediated abacavir hypersensitivity.71–73 Two 
major clinical trials, the PREDICT-1 (Prospective Random-
ized Evaluation of DNA Screening in a Clinical Trial) and 
SHAPE (Study of Hypersensitivity to Abacavir and Phar-
macogenetic Evaluation) studies, utilized skin patch testing 
as immunologic confirmation of abacavir hypersensitivity in 
their study design.74,75 The PREDICT-1 study was a random-
ized double-blind controlled study, randomizing patients to 
receive real-time HLA-B*5701 screening to exclude abacavir 
in those who tested positive on initiation of abacavir and 
clinical monitoring with later HLA-B*5701. The study was 
the first of its type to study the effectiveness of a genetic test 
to reduce a specific drug toxicity. It enrolled almost 2000 
patients of predominant Caucasian ethnicity and demonstrated 
that HLA-B*5701 screening eliminated immunologically 
confirmed abacavir hypersensitivity.74 The SHAPE study, 
which was a case-control study of black and white patients 
in the US, demonstrated that 100% of both white and black 
patch test-positive patients with a clinical history consistent 
with abacavir hypersensitivity carried HLA-B*5701.75 Col-
lectively, the PREDICT-1 and SHAPE studies hence provided 
strong evidence for the clinical utility of HLA-B*5701 to 
prevent abacavir hypersensitivity, generalizable across race.
In addition, several observational studies have   convincingly 
shown the benefits of HLA-B*5701 screening to eliminate 
both true immunologically mediated abacavir hypersensitivity 
and false-positive clinical diagnosis.76–82 Convergent with 
evidence supporting the clinical utility of HLA-B*5701 
as a screening test to prevent abacavir hypersensitivity 
was a body of basic science that suggested HLA-B*5701 
was necessary but not sufficient for the development of 
  abacavir hypersensitivity.83,84 In addition, feasible molecular 
  techniques with rapid   turnaround times were developed that 
were   cost-effective alternatives to sequence-based typing.85–89 
An HLA-B*5701-specific quality assurance program was 
validated and is currently actively administered by the 
  Asia-Pacific Histocompatibility and Immunogenetics Asso-
ciation.90 HLA-B*5701 testing prior to initiation of abacavir 
ART is currently recommended as part of major HIV treat-
ment guidelines and represents a success story in the transla-
tion of a pharmacogenetic testing to the routine clinic setting 
and provides a translational roadmap in this regard.
Nevirapine
Nevirapine is an NNRTI used in combination ART that has 
an excellent long-term toxicity profile. The major treatment-
limiting toxicity of nevirapine is a rash, hypersensitivity 
syndrome, and hepatitis that typically occurs within 2–8 
weeks of treatment initiation in approximately 5% of those 
starting the drug.91 SJS/TEN are rare and life-threatening 
severe skin syndromes that occur in 0.3% of those starting 
nevirapine within 8 weeks of treatment initiation.91 Unlike 
abacavir hypersensitivity, which was associated with a single 
HLA class I allele, different class I and class II associations 
have been associated with nevirapine rash, hypersensitiv-
ity, and hepatitis. In 2005, a population-based study from 
Western Australia was the first to associate HLA-DRB1*0101 
with nevirapine rash-associated hepatitis in the setting of 
CD4%$25.92 Subsequently, other groups have published 
class I HLA association with nevirapine hypersensitivity such 
as HLA-B*1402 and HLA-Cw8 in a Sardinian population,93 
HLA-Cw8 in a Japanese population,94 and HLA-B*3505 in 
association with nevirapine rash and hypersensitivity in a Thai 
population.95 In an updated analysis of the Western Australian 
cohort study, the initial association of HLA-DRB1*0101 
and CD4%$25 was again confirmed with nevirapine rash-
associated hepatitis, but an additional class I association 
between HLA-B*3501 and nevirapine hypersensitivity with 
rash became apparent.96 This analysis also suggested that 
ethnicity and phenotype are important and, in particular, that 
HLA-DRB1*0101 is associated with a hepatitis phenotype 
in Caucasians, whereas HLA-B*35 is associated with a rash 
phenotype across populations.Pharmacogenomics and Personalized Medicine 2012:5 submit your manuscript | www.dovepress.com
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Yuan et al97 also recently published data from the 
Boerhringer-Ingelheim protocol 1100.1452, which also 
underscored the phenotype and ethnicity specific nature of 
nevirapine rash, hypersensitivity, and hepatitis. This study 
was a case-control format that enrolled 889 patients across 
76 sites comprising 276 cases and 587 controls with CD4 
cell counts $150 cells/µL at the start of treatment. This 
study used only two-digit HLA typing but similarly associ-
ated HLA-DRB1*01 with hepatitis in white, HLA-B*35 and 
HLA-Cw*04 with rash in Asian, and HLA-Cw*04 with rash 
in white and black   populations.97 In addition, the CYP2B6 
slow metabolizer genotype 516 G.T appeared to associate 
with rash rather than hepatitis. Previous studies had also 
associated the drug transporter genetic polymorphism MDR1 
3435 C.T with a decreased risk of nevirapine hepatotoxic-
ity, and another African study associated CYP3A5 6986 
A.G and MDR1 3435 C.T with increases in liver enzymes 
in relation to nevirapine.98–100 Another recently presented 
case-control analysis involved examining high-resolution 
HLA class I and II typing in South Africans initiating nevi-
rapine as part of protocol FTC−302. This study associated 
HLA-DRB1*0102, a class I allele with sequence homology 
to HLA-DRB1*0101, and nevirapine-associated hepato-
toxicity.101 Another study that used HLA two-digit typing 
showed an association between both efavirenz rash, nevi-
rapine hypersensitivity, and HLA-DRB1*01.102   Collectively, 
these nevirapine studies imply that different metabolic, 
immunologic, and genetic factors contribute to nevirapine 
hypersensitivity across different populations. Although it will 
further our understanding of the pathogenesis of nevirapine 
hypersensitivity syndromes, it seems unlikely at this point in 
time, given the diversity of associations and their complexity 
across populations, that HLA or other genetic tests could be 
feasibly applied in the clinical setting to prevent nevirapine 
rash, hepatitis, and hypersensitivity. For severe skin reactions 
such as SJS/TEN associated with nevirapine, a specific HLA 
association has yet to be defined, although genetic factors 
appear likely, with a case report of nevirapine SJS/TEN 
occurring in two family members.
Drug reactions not thought to be 
exclusively immunologically mediated
Nucleoside/nucleotide reverse transcriptase  
inhibitors
Mitochondrial toxicities: peripheral neuropathy
Peripheral neuropathy in the setting of ART has been 
  particularly associated with the so-called d drugs, including 
the dideoxy-NRTIs (dNRTIs [ddI, ddC]) and the thymidine 
analog d4T (ddC.d4T.ddI).103 The risk tends to be higher 
in small females, when d4T and ddI are used together, and 
with advanced age and HIV disease. After 1 year of d-NRTI 
treatment, the incidence is estimated to be 10%–25%. In 
comparison with HIV-associated peripheral neuropathy, the 
quality of pain is similar with symmetric painful   dysesthesias 
and sensory loss. However, the onset of ART-induced periph-
eral neuropathy tends to be abrupt and will be   partially 
  alleviated by ceasing the offending ARTs. Mounting   evidence 
has suggested that drug-induced mitochondrial toxicity and 
inflammatory damage to the axons of peripheral nerves 
play a large part in the pathophysiology of ART-induced 
peripheral neuropathy. Candidate gene approaches have 
hence focused on genes related to mitochondrial function, 
NRTI metabolism, inflammatory response, apoptosis, and 
other factors where genetic variation could plausibly affect 
tendency to peripheral neuropathy, such as nutrient and 
antioxidant genes. Limited information currently exists on 
drug metabolism of NRTIs, as intracellular metabolite that 
correlates with efficacy and toxicity are difficult to measure. 
External factors that may increase concentrations of NRTI 
triphosphates such as hydroxyurea and ribavirin have been 
shown to increase the risk of NRTI-associated peripheral 
neuropathy and potentially other mitochondrial toxicities. 
Women, who have a higher risk of ART-associated periph-
eral neuropathy and other mitochondrial toxicities such as 
lipoatrophy and lactic acidosis, have also been shown to 
have significantly higher intracellular NRTI triphosphate 
concentrations. Mitochondrial DNA (mtDNA) is classified 
according to specific patterns of polymorphisms called hap-
logroups. In earlier studies, a common European mitochon-
drial haplogroup, haplogroup T (7028 C.T, 10398 G.A, 
and 13368 G.A) was associated with neuropathy during 
treatment in a case-control study from the ACTG 384.104 
A follow-on study showed that another variant at complex I, 
subunit ND2, 4917A.G, which has been associated with 
neurodegenerative diseases, was associated with ART-
associated peripheral neuropathy in the white population.105 
Iron is essential for mitochondrial function, and in subjects 
receiving d4T/ddI in ACTG 384, common polymorphisms 
in the hemochromatosis gene (HFE) 845 G.A and 187 
C.G have also been associated with a decreased risk of 
peripheral neuropathy.106 Because HFE is linked to the class 
I HLA-A3 allele, it needs to be ascertained that this effect 
is not due to linkage disequilibrium. Adding weight to the 
inflammatory pathogenesis of ART-associated peripheral 
neuropathy have been recent studies associating cytokine 
polymorphisms such as tumor necrosis factor-α (TNF-α) Pharmacogenomics and Personalized Medicine 2012:5 submit your manuscript | www.dovepress.com
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1031*2 and   markers of the 8.1 ancestral haplotype (HLA-A1/
B8/DR3) such as TNF-α 308*2 and B(0,+)-type amino acid 
transporter 1 (BAT1)*2.107,108 Interleukin 12B (IL12B)*2 gen-
otype was over-represented in subjects who did not develop 
peripheral neuropathy.108 A small study attempted to combine 
patient demographics with these cytokine polymorphisms 
into a predictive model for peripheral neuropathy.109
Mitochondrial toxicities: lipoatrophy
Lipoatrophy is a largely irreversible mitochondrial   toxicity 
that occurs largely in association with the thymidine 
  analogs d4T.AZT. Like other mitochondrial toxicities, it is 
  postulated that the toxicity is mediated by NRTI inhibition 
of DNA polymerase-γ in the host, which leads to depletion 
of mtDNA. In relation to other mitochondrial toxicities, a 
genetic variant of DNA polymerase-γ relating to 14% of 
functional activity was reported in a Thai patient with lactic 
acidosis related to d4T.110 With regards to lipoatrophy, risk is 
related to duration of treatment and is higher in females of 
lower body mass, suggesting a dose relationship. Previous 
fat biopsy studies have substantiated the early depletion of 
mtDNA preceding clinical disease and have highlighted 
the impressive active inflammatory response present in the 
fat in this disease. A promoter polymorphism in the TNF-α 
gene (TNF-238 A) has been associated with more rapid 
progression of disease.111,112 Mitochondrial haplogroup H 
was associated with increased thymidine analog-associated 
limb lipoatrophy and the HFE 187 C.G with less periph-
eral lipoatrophy.113,114 In another study, polymorphisms 
in IL-1β 3954 C.T were also associated with protection 
against lipoatrophy associated with thymidine analogs.115 
In a separate study from ACTG 5005s and 384, an SNP in 
the resistin gene 7640369 C.T was associated positively 
with lipoatrophy.116 More recently, in a Thai case-control 
study, HLA-B*4001 was associated with moderate to severe 
lipoatrophy, defined by anthropomorphic measurements, 
questionnaire, and dual-emission x-ray absorptiometry scan, 
with a negative predictive value of 54%.117 These results 
would need to be verified. In particular, it ascertained that 
this was not due to linkage disequilibrium. In contemporary 
HIV practice in the developed world, new cases of lipoa-
trophy are being avoided through prevention and lack of 
use of thymidine analogs in first-line therapy. Challenges 
still exist in the developing world, where the demograph-
ics may independently put patients at risk for thymidine 
analog-associated mitochondrial toxicities. In addition, 
there is a significant burden of patients with past exposure 
to thymidine analogs.
Renal toxicity
Tenofovir disoproxil fumarate is the orally bioavailable 
prodrug of tenofovir that is an acyclic nucleotide reverse 
transcriptase inhibitor that is available in fixed-dose 
combination with emtricitibine and efavirenz. Tenofovir is 
eliminated unchanged in the kidney and has been associ-
ated with various presentations of nephrotoxicity, includ-
ing proximal renal tubular dysfunction with and without 
decreased renal function. Although serious events occur 
in ,1% of patients, approximately 2% will develop a 
significant increase in creatinine.118,119 Demographic factors 
that have been associated with tenofovir nephrotoxicity have 
included lower body weight, pre-existing renal dysfunction, 
medical comorbidities, concurrent nephrotoxic medications, 
advanced HIV , and advanced age. Some studies have also 
suggested a higher risk of developing renal impairment 
when tenofovir is used in combination with ritonavir-boosted 
protease inhibitors.120 Currently, the exact mechanism by 
which tenofovir causes renal toxicity is unclear and has been 
postulated to be mitochondrial toxicity similar to the related 
nucleotide analogs adefovir and cidofovir or direct interfer-
ence with tubular function. Around 20%–30% of tenofovir 
is actively transported into renal proximal tubular cells by 
organic anion transporters hOAT1 (encoded by the solute car-
rier family 22 [SLC22] A6 gene) and OAT3. The membrane 
transporter multidrug resistance-associated protein (MRP) 
4 encoded by the ATP-binding cassette sub-family C (ABC) 
C4 gene is primarily responsible for secreting the drug into 
the tubular lumen and into the urine, and the ABCC4 3463 
variant has been associated with intracellular concentra-
tions 35% higher than wildtype. Although MRP2 has not 
been shown to have a clear role in tenofovir excretion, two 
studies have shown associations between polymorphisms 
in the ABCC2 gene, which encodes MRP2 and tenofovir 
proximal tubulopathy, and the exact mechanism of this 
remains to be determined.121,122 One case-control study 
associated a specific CATC haplotype (polymorphisms-24, 
1249, 3563, and 3972) in ABCC2 and proximal tubular 
disease, whereas another cross-sectional study, which used 
a different definition of renal toxicity, associated tenofovir 
tubular damage with the ABBC2-24C allele but not the 
CATC high-risk haplotype. Despite the fact that MRP4 is the 
primary transporter involved in the excretion of tenofovir, 
studies of genetic variation in association with tenofovir 
renal toxicity have been inconsistent, with one study sug-
gesting an association with the polymorphism ABCC4 669 
C.T in those with tenofovir renal damage but other studies 
looking at this and a larger number of SNPs not confirming Pharmacogenomics and Personalized Medicine 2012:5 submit your manuscript | www.dovepress.com
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this association.123 Polymorphisms in other transporter genes 
such as SLC22A6 and P-glycoprotein (coded by the ABCB1 
gene) have shown no association with tenofovir clearance, 
levels, or renal damage. Recent evidence has suggested a 
role for ABCC10 (MRP7), a renal efflux transporter func-
tionally similar to ABCC2, in the transport of tenofovir. 
Two ABCC10 SNPs (rs9349256 and rs2125739) and their 
haplotype were more commonly represented in 19 cases with 
tenofovir renal disease versus 96 tenofovir-tolerant controls 
without renal disease.124 Collectively, these findings are too 
preliminary to be used predictively in the clinic setting, and 
more studies using standardized definitions of renal toxicity 
and looking at generalizability across different populations 
will be needed to further clarify the pharmacogenetics of 
tenofovir toxicity.
Protease inhibitors
Unconjugated hyperbilirubinemia
Atazanavir and indinavir have commonly been associated 
with unconjugated hyperbilirubinemia due to inhibition 
of   bilirubin binding to uridine diphosphate gluronosyl-
  transferase 1A1 (UGT1A1), and hence the inhibition and 
clearance of bilirubin.125 In view of dosing and toxicity 
considerations, indinavir is not commonly used in clinical 
practice. For atazanavir, it has been shown that there is a direct 
correlation between unconjugated hyperbilirubinemia and 
atazanavir plasma levels.126,127 Patients who have received indi-
navir and atazanavir are more likely to develop unconjugated 
hyperbilirubinemia if they have Gilbert syndrome, a genetic 
defect resulting from the promoter polymorphism in the TAT 
region of UGT1A1 (UGT1A1*28), which is independently 
associated with reduced bilirubin-conjugating activity.128 
Polymorphisms in this promoter region are most important 
in the unconjugated hyperbilirubinemia associated with 
atazanavir in Caucasians. However, other polymorphisms 
such as the UGT1A1*6 (211 G.A) may be more important 
in the Asian population.129–131 Studies from clinical trials 
and clinical practice have documented that between 20% 
and 50% of patients exposed to atazanavir will develop 
unconjugated hyperbilirubinemia, of which up to 6% will 
be clinically apparent. Efavirenz has been shown to reduce 
unconjugated hyperbilirubinemia by its inducing effect on 
UGT1A1.132 Atazanavir plasma levels may also be affected 
by the P-glycoprotein drug transporter gene MDR1, with 
patients with the MDR1 3435 C.T polymorphism showing 
higher atazanavir plasma levels.133 Although unconjugated 
hyperbilirubinemia has no direct clinical consequences in 
adults, the effects of clinical jaundice may be cosmetically 
disturbing, and some studies have suggested a correlation 
between genetics and early treatment discontinuation of 
atazanavir in treatment-naive patients.134 There are currently, 
however, no studies that directly support the use of genetic 
screening in the routine clinical use of atazanavir.
Metabolic disturbances
Candidate gene studies in HIV-infected patients have focused 
on genetic variation in apolipoprotein E (APOE) and the 
gene cluster APOA1/C3/A4/A5 due to associations between 
polymorphisms in this group with hyperlipidemia in the 
general population. Some of these same SNPs have been 
examined in HIV-infected populations to add insights into 
the contribution of drugs and genetics to the dyslipidemia 
that is commonly seen in this population. Polymorphisms in 
APOA5 have been implicated, in that individuals not carry-
ing the APOA5 *1/*1 haplotype (113IT.C, 64 G.C) have 
been shown to be at risk for low high-density lipoprotein 
cholesterol and hypertriglyceridemia in association with 
ritonavir.135,136 In this Swiss cohort predominantly Cauca-
sian study, which longitudinally followed 438 HIV-infected 
patients for a median of 4.8 years across different ART 
regimens, SNPs in ABCA1, APOC3, APOE, APOA5, and 
cholesteryl ester transfer protein (CETP) aversely affected 
plasma triglyceride, and APOA5 and CETP were associated 
with low high-density lipoprotein cholesterol. The Swiss 
cohort group further validated the potential contribution of 
42 SNPs, 33 of which had been reported in HIV-negative 
genome-wide association studies to dyslipidemia in 745 
HIV-infected subjects.136 Taiwanese patients carrying APOA5 
553 G.T had a higher risk of protease inhibitor-associated 
hypertriglyceridemia.137 Carriage of APOE ε4 has been asso-
ciated with hypertriglyceridemia in HIV-positive patients not 
taking ART.138 Carriers of other variants of APOE also appear 
to be at risk for ritonavir-associated hypertriglyceridemia, 
and this risk appears to be enhanced in association with 
APOC3 variants.139,140 Collectively, these findings indicate 
that many genetic factors common to the general population 
are associated with hyperlipidemia in HIV and particularly 
during protease inhibitor therapy. Larger studies are needed 
to investigate associations between these gene variants, ART, 
and other vascular and metabolic events in HIV-infected 
individuals.
Non-nucleoside reverse transcriptase inhibitors
Neuropsychiatric disturbances
Up to two-thirds or more of patients initiating efavirenz will 
experience some degree of CNS side effects, which can be Pharmacogenomics and Personalized Medicine 2012:5 submit your manuscript | www.dovepress.com
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characterized by the full spectrum of minor sleep disturbances 
and vivid dreams through to major depression and anxiety. 
Most patients report amelioration of these symptoms by 2–4 
weeks of treatment. However, up to 10% of patients have 
persistent symptoms that lead to efavirenz discontinuation.141 
Not all studies have shown an association between efavirenz 
plasma levels and neuropsychiatric side effects.142 Many stud-
ies have confirmed associations between CYP2B6 variants, 
including CYP2B6 516 G.T and efavirenz exposure, and 
some have also suggested an association between CYP2B6 
variants and early CNS toxicity.16,20,21,24–44 A recent study 
suggested an increased association with plasma efavirenz 
exposure and CNS events in white patients and a composite 
CYP2B6 516 G.T and 983 T.C genotype.25 This same 
genotype was associated with decreased virologic failure 
in black patients. A recent study also associated efavirenz 
plasma concentrations with a polymorphism 540 C.T in the 
constitutive androstone receptor (CAR), which appears to be 
important in the regulation of CYP2B6.143 A recent cohort 
study of patients who had initiated efavirenz therapy showed 
the CAR C/C genotype and the CYP2B6 516 T/T genotype 
to be independently associated with efavirenz early treatment 
discontinuation, with patients who carried both polymor-
phisms having a higher rate of discontinuation.143 More recent 
studies indicated that a high proportion of patients with at-risk 
genotypes have both high efavirenz exposure and CNS side 
effects, suggesting that combined genotyping-therapeutic 
drug monitoring (TDM) approaches may be useful to guide 
efavirenz therapy, particularly in higher-risk populations.11 
Gatanaga et al24 looked at approaches combining genotyping 
and TDM. They showed consistently high efavirenz expo-
sure in the CYP2B6 516 G.T variants *6/*6 and *6/*26. 
With daily dose reductions to 400 mg (n = 11) and 200 mg 
(n = 7), they were able to maintain virologic suppression 
and improve CNS side effects in .70% of patients.
Implications for clinical use:  
patient considerations
With a number of different combination regimens available 
for treatment of the HIV patient, individualized approaches 
to therapy have become both feasible and necessary in many 
cases. Individualized approaches to ART leading to the 
personalized antiretroviral prescription are driven not only 
by host factors but also by specific attributes of the virus 
and drugs being prescribed (Figure 2). Host factors that are 
increasingly important in driving a personalized approach 
to HIV therapy include pharmacoecologic factors relevant 
to individual patients such as lifestyle and adherence issues, 
food and drug-drug interactions, pregnancy, and underlying 
organ dysfunction, as well as hepatitis B/C coinfection 
(Figure 2). The increasing burden of non-AIDS morbidities, 
trends to initiate ART earlier, and the long period of time an 
individual patient would ideally spend on a single regimen 
also drive the need for individualized approaches to ART to 
ensure long-term success. Early approaches to individualiza-
tion of ART included TDM, which was particularly pertinent 
to early protease inhibitor-based regimens because of the 
high interindividual variability of drug levels and the util-
ity of increasing drug exposure in treatment-experienced 
patients. Although early studies of TDM showed promise, 
TDM of protease inhibitors was not shown to be beneficial 
in one randomized study of treatment-experienced patients 
(ACTG5146), where a normalized ratio of the protease inhibi-
tor concentration in relation to its 50% inhibitory concentra-
tion (IC50) was used to dose adjust patients and the primary 
endpoint was virologic response at 20 weeks.144,145 However, 
it was noted in this study that TDM appeared to be more 
beneficial in patients with less viral resistance, suggesting 
that the specific population selected may have been important, 
and that TDM may benefit select populations of treatment-
experienced patients.145 Nonetheless, measuring drug con-
centrations has remained a useful tool in clinical practice 
for individualizing patient therapy, particularly in cases of 
complex drug–drug interactions, in verifying patient compli-
ance, and in other states, such as later stages of pregnancy 
where pharmacokinetics of certain protease inhibitors such as 
lopinavir/ritonavir may be altered and exposure reduced.146,147 
Although there has been an explosion of pharmacogenetic/
pharmacogenomic literature relevant to the field of HIV , it 
is anticipated that most of this knowledge will not be used 
to develop specific pharmacogenetic tests that are relevant 
to the treatment of the individual patient. In view of this 
continued influx of new literature, the website http://www.
hiv-pharmacogenomics.org/ represents a useful reference 
for the reader, where tables of the pharmacogenetics of ART 
with reference to the pharmacokinetics, pharmacodynamics, 
reproducibility, and clinical relevance of pharmacogenetic 
associations are regularly updated.148
Although few pharmacogenetic associations will be 
directly translated into clinical practice, such knowledge 
has significantly furthered our understanding of the patho-
genesis of host virus interactions, drug disposition, drug 
interactions, drug efficacy, and toxicity. Such knowledge also 
has future implications, such as to aid in the development 
of new drug targets and identify ways for screening drugs 
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of drug development. Several steps are required to bring a 
pharmacogenetic test from discovery through to translation 
as a pharmacogenetic test in clinical practice.149 Factors 
influencing the success of translation include encompassing 
the right combination of characteristics of the test, the drug, 
the drug toxicity, the availability, or the ability to generate 
high levels of evidence and pharmacoeconomic data to 
support the test and having the right clinical and laboratory 
environment and infrastructure, including appropriate quality 
assurance programs. Robust partnerships between academia 
and pharma are also helpful in this process.
Finally, the actual pharmacogenetic test report needs to be 
easy to interpret and implemented by clinicians, and it must 
be readily understood and acted upon by both the healthcare 
system and patients. HLA-B*5701 testing for abacavir is one 
example of a test that has translated from discovery into a 
guideline-based routine HIV clinical practice, and even with 
the aforementioned factors being put into place and a simple 
and interpretable reporting scheme, this test took approxi-
mately 6 years from discovery to clinical implementation. 
Given that drug toxicities are still the most common reason 
why treatment-naive HIV patients discontinue treatment in 
the first year of therapy, it seems logical that pharmacogenet-
ics could help identify the right drug regimen for the right 
patient. A recent observational cohort study that examined 
the association of pharmacogenetics with the time to treat-
ment discontinuation during the first year of ART found that 
discontinuation rates were significantly higher for efavirenz- 
and atazanavir-based regimens in patients carrying high-risk 
genetic markers that had been previously shown to correlate 
with toxicity or pharmacokinetics of these drugs.134
Although it is intriguing that pharmacogenetics could 
inform more intelligent antiretroviral prescribing, other than 
for HLA-B*5701 and abacavir, prospective approaches to 
treatment using pharmacogenetic information to initiate 
ART have not been studied. Cost-effectiveness is uncertain, 
and the clinical, laboratory, and reporting infrastructure to 
implement such programs would be currently lacking at 
most centers. IL28B is a gene encoding for interferon-λ, a 
cytokine with antiviral activity. Three independent genome-
wide association studies published in 2009 associated 
variation around the IL28B gene with treatment response to 
pegylated interferon and ribavirin for genotype 1 hepatitis C 
infection.150–152 HIV/hepatitis C virus coinfected patients with 
genotype 1 virus typically have a poor treatment response to 
pegylated interferon and ribavirin therapy. However, IL28B 
genotype also appears to affect treatment response in this 
population, even in those who have failed prior treatment, and 
may be useful to identify patients for whom early treatment 
would be warranted.153,154
Conclusions and future perspectives
Individualization of ART represents an important compo-
nent of day-to-day HIV practice, given the diversity of drugs 
available, viral factors, and increasing diversity in HIV treat-
ment populations. Over the last 5–10 years, a vast amount of 
published literature has been generated in the fields of HIV 
and antiretroviral pharmacogenetics and pharmacogenomics. 
Most of these discoveries, although not readily applicable to 
the clinic, will continue to guide our understanding of dis-
ease processes and antiretroviral efficacy and toxicity. Host 
pharmacogenetics currently play a minor role in our approach 
to individualization of drug therapy, although HLA-B*5701 
screening for abacavir hypersensitivity represents an unusual 
example of  a test that has been successfully translated from 
discovery to widespread clinical practice, and provides a gen-
eral translational roadmap for other pharmacogenetics tests.
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